Synergistic Activity of Combined Inhibition of Anti-apoptotic Molecules in B-cell Precursor ALL

When analyzing the effects of BH3-mimetics selectively targeting BCL-XL and MCL-1 alone or in combination with the BCL-2 inhibitor venetoclax, heterogeneous sensitivity to either of these inhibitors was found in ALL cell lines and in patient-derived xenografts.